1. Home
  2. GKOS vs URBN Comparison

GKOS vs URBN Comparison

Compare GKOS & URBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • URBN
  • Stock Information
  • Founded
  • GKOS 1998
  • URBN 1970
  • Country
  • GKOS United States
  • URBN United States
  • Employees
  • GKOS N/A
  • URBN N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • URBN Clothing/Shoe/Accessory Stores
  • Sector
  • GKOS Health Care
  • URBN Consumer Discretionary
  • Exchange
  • GKOS Nasdaq
  • URBN Nasdaq
  • Market Cap
  • GKOS 5.5B
  • URBN 6.5B
  • IPO Year
  • GKOS 2015
  • URBN 1993
  • Fundamental
  • Price
  • GKOS $100.14
  • URBN $67.95
  • Analyst Decision
  • GKOS Strong Buy
  • URBN Buy
  • Analyst Count
  • GKOS 13
  • URBN 11
  • Target Price
  • GKOS $135.15
  • URBN $74.73
  • AVG Volume (30 Days)
  • GKOS 909.8K
  • URBN 2.5M
  • Earning Date
  • GKOS 07-30-2025
  • URBN 05-21-2025
  • Dividend Yield
  • GKOS N/A
  • URBN N/A
  • EPS Growth
  • GKOS N/A
  • URBN 52.13
  • EPS
  • GKOS N/A
  • URBN 4.77
  • Revenue
  • GKOS $404,523,000.00
  • URBN $5,679,435,000.00
  • Revenue This Year
  • GKOS $27.88
  • URBN $10.49
  • Revenue Next Year
  • GKOS $27.60
  • URBN $6.69
  • P/E Ratio
  • GKOS N/A
  • URBN $14.20
  • Revenue Growth
  • GKOS 23.92
  • URBN 8.38
  • 52 Week Low
  • GKOS $77.10
  • URBN $33.86
  • 52 Week High
  • GKOS $163.71
  • URBN $75.80
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 58.49
  • URBN 53.25
  • Support Level
  • GKOS $97.54
  • URBN $67.19
  • Resistance Level
  • GKOS $102.82
  • URBN $71.36
  • Average True Range (ATR)
  • GKOS 3.51
  • URBN 2.42
  • MACD
  • GKOS 0.67
  • URBN -0.90
  • Stochastic Oscillator
  • GKOS 77.52
  • URBN 11.26

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About URBN Urban Outfitters Inc.

Founded in 1970, Philadelphia-based Urban Outfitters is an apparel and home goods retailer that operates more than 700 stores and e-commerce in the United States, which accounts for about 87% of sales, and other regions. Its retail nameplates are Urban Outfitters (23% of fiscal 2025 sales), Free People/Movement (26%), and Anthropologie (44%). Retail accounted for 88% of fiscal 2025 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (7% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.

Share on Social Networks: